LOXITANE (loxapine succinate) by Teva is clinical pharmacology pharmacodynamics pharmacologically, loxapine is an antipsychotic for which the exact mode of action has not been established. Approved for schizophrenia, comatose, severe drug-induced depressed states (alcohol and 3 more indications. First approved in 1975.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
LOXITANE (loxapine succinate) is a first-generation antipsychotic tablet approved in 1975 for treating schizophrenia and severe drug-induced depressed states. The exact mechanism remains unclear, but it reduces excitability in subcortical inhibitory areas, producing sedation and behavioral calming within 20–30 minutes. The drug is rapidly absorbed, extensively metabolized, and excreted primarily within 24 hours.
As loss of exclusivity approaches, the brand team will likely shrink; career opportunities may shift toward generic optimization or transition to higher-growth products.
CLINICAL PHARMACOLOGY Pharmacodynamics Pharmacologically, loxapine is an antipsychotic for which the exact mode of action has not been established. However, changes in the level of excitability of subcortical inhibitory areas have been observed in several animal species in association with such…
Worked on LOXITANE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Fasting Study of Loxapine Succinate Capsules 25 mg and Loxitane® Capsules 25 mg
LOXITANE offers minimal career growth opportunity; linked job postings are zero, reflecting the product's LOE status and limited commercial footprint. Roles are primarily transactional (defending remaining market share, generic transition) rather than strategic.